Bausch Health's agreement to acquire Allegro's ophthalmology assets will help its long-term strategy for growth, according to an analysis Sept. 30 published in Pharmaceutical Technology.
Allegro has two pipeline projects: Risuteganib, an integrin-regulating therapy being evaluated in dry atrophic macular degeneration, and ALG-1007, a topical integrin regulator being evaluated in dry eye syndrome, the report said. These assets are expected to expand Bausch's pipeline and open up the possibility to dip into the commercial market for the indications, especially in dry AMD.
Drug sales in the dry AMD and DES markets are expected to grow, the report said.
Read more details and the full analysis here.
More articles on surgery centers:
Florida eye practice to expand
U of Michigan doctor's work on 'Mini-Vit' to help precision medicine in ophthalmology
7 ophthalmology deals in the last 90 days